Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Cetrotide. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 15, 2026, FDA lists 7 applications for Cetrorelix Acetate (sold as Cetrotide), first approved Aug 11, 2000, with 0 new uses approved and 0 published complete response letters.
First approved: Aug 11, 2000
Applications: 7
New uses approved: 0
Complete response letters: 0
First approved in the EU: Apr 12, 1999
Approvals in the EU (EMA)
First approved in the EU 16 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
CetrotideA drug with a new dosage indicated for the prevention of premature ovulation during controlled ovarian stimulation. · Nippon Kayaku Co., Ltd. · Sep 16, 2022
Clinical Trials
13 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
